Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

However, significant research has been completed on IL-17 inhibitors like lutikizumab, izokibep, and sonelokimab. Additional research is needed to determine which patients have the most robust ...

The newer biologics — interleukin (IL)-17, IL-12/23, and IL-23 inhibitors — have cardiovascular safety profiles comparable with those of tumor necrosis factor (TNF) inhibitors in biologic ...

Immune-targeted therapies, such as IL-17 and IL-23 inhibitors, can effectively treat psoriasis, but their high cost and long-term systemic immunosuppressive risks can limit their use. Here ...